Albeit CD19-CAR T cell as well as anti-Hu5F9 monotherapy showed antitumor activity to some extent, CD19-s47-CAR T cells further decreased tumor burden and prolonged the survival time of mice compared with monotherapy groups, achieving comparable effect with the combined treatment group. Here, CD19 is linked to neoplasm.